Please join ITIF, the Geneva Network, and the University of Akron School of Law for an event releasing a new report profiling 24 pioneering case studies from five regions—Latin America, Africa, South Asia, Southeast Asia, and Middle East and North Africa—where IP rights have enabled innovators to create impactful health solutions, particularly in the developing world.

Watch now for an expert panel discussion surrounding the ITIF report examining why the United States lost its lead in other advanced technology industries, and how policymakers can avoid repeating the same mistakes in the biopharmaceutical sector.

Tune in for an expert panel discussion examining where Japan faltered in this sector, what it must do to restore its life-sciences innovation leadership and competitiveness, why that would be in the best interests of both Japan and the United States—and what America must do to avoid following in Japan’s footsteps.

Watch the release event of a new report that examines the dynamics that underpin the economics of biopharmaceutical innovation and how to maintain a supportive environment that keeps the United States in the lead of life-sciences innovation.

ITIF hosted a panel discussion with leading experts on innovation policy, technology transfer, and business, who spoke to the practical implications of exercising federal “march-in” rights and why it would be a grave and ill-timed mistake for the U.S. health, competitiveness, and research landscape.

AI has the potential to cut drug development times nearly in half, and ITIF’s new report highlights the transformative impact and policy needs to make it happen.

AI has the potential to transform drug development by enhancing productivity across the entire development pipeline, boosting biopharmaceutical innovation, accelerating the delivery of new therapies, and fostering competition to help improve public health outcomes.

Mario Draghi's 2024 report addresses the EU's biopharmaceutical decline, citing challenges like underfunded research, fragmented pricing, and competition from the U.S. and China. It recommends reforms but underplays the impact of EU drug price controls on innovation.

The Information Technology and Innovation Foundation will offer grants for new research that helps to inform the relationship between the expectation of a financial reward for an approved new drug or new indication in the United States and the (1) investment in research and development for new and existing drugs, and/or (2) the approval of new drugs and new indications.

Selena is transforming eye care by leveraging AI to detect diseases like diabetic retinopathy with unprecedented accuracy, helping to diagnose issues early and prevent blindness, thus improving patient outcomes and offering more access globally.

TauRx is revolutionizing Alzheimer's treatment with a novel drug that targets toxic brain proteins, offering fresh hope in the fight against this devastating disease.

InCurA is revolutionizing MENA's medical landscape with AI-optimized, locally produced hemostatic solutions like CurASeal, bridging the gap between innovation and accessibility while reducing reliance on global imports.